399 related articles for article (PubMed ID: 28606110)
21. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.
Zhang K; Donnelly CJ; Haeusler AR; Grima JC; Machamer JB; Steinwald P; Daley EL; Miller SJ; Cunningham KM; Vidensky S; Gupta S; Thomas MA; Hong I; Chiu SL; Huganir RL; Ostrow LW; Matunis MJ; Wang J; Sattler R; Lloyd TE; Rothstein JD
Nature; 2015 Sep; 525(7567):56-61. PubMed ID: 26308891
[TBL] [Abstract][Full Text] [Related]
22. [Impact of C9orf72 on Japanese Patients with Amytrophic Lateral Sclerosis (ALS)/Frontotemporal Dementia (FTD)].
Tomiyama H
Brain Nerve; 2019 Nov; 71(11):1190-1208. PubMed ID: 31722305
[TBL] [Abstract][Full Text] [Related]
23. UPF1 reduces C9orf72 HRE-induced neurotoxicity in the absence of nonsense-mediated decay dysfunction.
Zaepfel BL; Zhang Z; Maulding K; Coyne AN; Cheng W; Hayes LR; Lloyd TE; Sun S; Rothstein JD
Cell Rep; 2021 Mar; 34(13):108925. PubMed ID: 33789100
[TBL] [Abstract][Full Text] [Related]
24. G-Quadruplexes Formation by the
Zhang Y; Huang J; Yu K; Cui X
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375224
[TBL] [Abstract][Full Text] [Related]
25. Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia.
Gagliardi D; Costamagna G; Taiana M; Andreoli L; Biella F; Bersani M; Bresolin N; Comi GP; Corti S
Ageing Res Rev; 2020 Dec; 64():101172. PubMed ID: 32971256
[TBL] [Abstract][Full Text] [Related]
26. RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3.
Ramesh N; Daley EL; Gleixner AM; Mann JR; Kour S; Mawrie D; Anderson EN; Kofler J; Donnelly CJ; Kiskinis E; Pandey UB
Acta Neuropathol Commun; 2020 Oct; 8(1):177. PubMed ID: 33129345
[TBL] [Abstract][Full Text] [Related]
27. Inflammasome-Mediated Neuronal-Microglial Crosstalk: a Therapeutic Substrate for the Familial C9orf72 Variant of Frontotemporal Dementia/Amyotrophic Lateral Sclerosis.
Trageser KJ; Yang EJ; Smith C; Iban-Arias R; Oguchi T; Sebastian-Valverde M; Iqbal UH; Wu H; Estill M; Al Rahim M; Raval U; Herman FJ; Zhang YJ; Petrucelli L; Pasinetti GM
Mol Neurobiol; 2023 Jul; 60(7):4004-4016. PubMed ID: 37010807
[TBL] [Abstract][Full Text] [Related]
28. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD.
Liu Y; Pattamatta A; Zu T; Reid T; Bardhi O; Borchelt DR; Yachnis AT; Ranum LP
Neuron; 2016 May; 90(3):521-34. PubMed ID: 27112499
[TBL] [Abstract][Full Text] [Related]
29. Genetic and epigenetic disease modifiers in an Italian
Ratti A; Peverelli S; D'Adda E; Colombrita C; Gennuso M; Prelle A; Silani V
Amyotroph Lateral Scler Frontotemporal Degener; 2022 May; 23(3-4):292-298. PubMed ID: 34382491
[No Abstract] [Full Text] [Related]
30. Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD.
Andrade NS; Ramic M; Esanov R; Liu W; Rybin MJ; Gaidosh G; Abdallah A; Del'Olio S; Huff TC; Chee NT; Anatha S; Gendron TF; Wahlestedt C; Zhang Y; Benatar M; Mueller C; Zeier Z
Mol Neurodegener; 2020 Feb; 15(1):13. PubMed ID: 32093728
[TBL] [Abstract][Full Text] [Related]
31. Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs.
Nguyen L; Laboissonniere LA; Guo S; Pilotto F; Scheidegger O; Oestmann A; Hammond JW; Li H; Hyysalo A; Peltola R; Pattamatta A; Zu T; Voutilainen MH; Gelbard HA; Saxena S; Ranum LPW
Neuron; 2020 Nov; 108(4):784-796.e3. PubMed ID: 33022226
[TBL] [Abstract][Full Text] [Related]
32. Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD.
Odeh HM; Shorter J
Emerg Top Life Sci; 2020 Dec; 4(3):293-305. PubMed ID: 32639008
[TBL] [Abstract][Full Text] [Related]
33. Molecular Mechanisms of Neurodegeneration Related to
Babić Leko M; Župunski V; Kirincich J; Smilović D; Hortobágyi T; Hof PR; Šimić G
Behav Neurol; 2019; 2019():2909168. PubMed ID: 30774737
[TBL] [Abstract][Full Text] [Related]
34. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.
Liu EY; Russ J; Wu K; Neal D; Suh E; McNally AG; Irwin DJ; Van Deerlin VM; Lee EB
Acta Neuropathol; 2014 Oct; 128(4):525-41. PubMed ID: 24806409
[TBL] [Abstract][Full Text] [Related]
35. Generation of a human induced pluripotent stem cell (iPSC) line (IBMS-iPSC-048-05) from a patient with ALS and parkinsonism having a hexanucleotide repeat expansion mutation in C9orf72 gene.
Lin HY; Tsai LK; Cheng YC; Lu HE; Huang CY; Hsieh PCH; Lin CH
Stem Cell Res; 2020 Apr; 44():101734. PubMed ID: 32151952
[TBL] [Abstract][Full Text] [Related]
36. BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS/FTD model.
Quezada E; Cappelli C; Diaz I; Jury N; Wightman N; Brown RH; Montecino M; van Zundert B
Clin Epigenetics; 2021 Mar; 13(1):56. PubMed ID: 33726839
[TBL] [Abstract][Full Text] [Related]
37. Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells.
Selvaraj BT; Livesey MR; Chandran S
Brain Pathol; 2017 Jul; 27(4):518-524. PubMed ID: 28585384
[TBL] [Abstract][Full Text] [Related]
38. Role of the C9ORF72 Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Hao Z; Wang R; Ren H; Wang G
Neurosci Bull; 2020 Sep; 36(9):1057-1070. PubMed ID: 32860626
[TBL] [Abstract][Full Text] [Related]
39. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72.
Zhu Q; Jiang J; Gendron TF; McAlonis-Downes M; Jiang L; Taylor A; Diaz Garcia S; Ghosh Dastidar S; Rodriguez MJ; King P; Zhang Y; La Spada AR; Xu H; Petrucelli L; Ravits J; Da Cruz S; Lagier-Tourenne C; Cleveland DW
Nat Neurosci; 2020 May; 23(5):615-624. PubMed ID: 32284607
[TBL] [Abstract][Full Text] [Related]
40. C9ORF72-ALS/FTD: Transgenic Mice Make a Come-BAC.
Hayes LR; Rothstein JD
Neuron; 2016 May; 90(3):427-31. PubMed ID: 27151634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
